argenex (NASDAQ:ARGX) Given New $940.00 Price Target at HC Wainwright

argenex (NASDAQ:ARGX) had its price target lifted by HC Wainwright from $915.00 to $940.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Other analysts have also recently issued research reports about the stock. DZ Bank raised shares of argenex to a “strong-buy” rating in a research report on Friday, December 19th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Wednesday, January 21st. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Wedbush reiterated an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research note on Wednesday, January 14th. Finally, Wolfe Research reissued a “peer perform” rating on shares of argenex in a research note on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $999.22.

argenex Stock Performance

Shares of argenex stock traded down $4.61 during trading hours on Friday, hitting $766.92. The company’s stock had a trading volume of 464,736 shares, compared to its average volume of 347,294. The stock has a market cap of $47.46 billion, a price-to-earnings ratio of 39.29, a P/E/G ratio of 0.67 and a beta of 0.37. argenex has a twelve month low of $510.05 and a twelve month high of $934.62. The firm has a fifty day moving average of $826.36 and a 200-day moving average of $810.76.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 26th. The company reported $8.02 EPS for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. argenex had a return on equity of 63.59% and a net margin of 30.42%.The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. On average, sell-side analysts expect that argenex will post 3.13 earnings per share for the current fiscal year.

Institutional Trading of argenex

Institutional investors and hedge funds have recently made changes to their positions in the company. Abound Wealth Management lifted its stake in argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after buying an additional 32 shares during the last quarter. Sound Income Strategies LLC acquired a new position in shares of argenex in the 4th quarter valued at $28,000. Ameriflex Group Inc. purchased a new stake in argenex in the 3rd quarter valued at $32,000. Aventura Private Wealth LLC acquired a new stake in argenex during the 4th quarter worth $38,000. Finally, Sunbelt Securities Inc. purchased a new position in argenex during the 3rd quarter worth $36,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

More argenex News

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.